查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1139948

溶酵素體貯積病治療市場：按疾病類型、按治療類型、按最終用戶：2021-2031 年全球機會分析和行業預測

Lysosomal Disease Treatment Market By Disease Type, By Type of Therapy, By End User : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 319 Pages | 商品交期: 2-3個工作天內

價格

全球溶酵素體貯積症治療市場預計將在 2021 年達到 75.7297 億美元，在 2031 年達到 140.9039 億美元，從 2022 年到 2031 年的複合年增長率為 6.4%。我在這裡。

溶酵素體貯積症是由酵素溶酵素體酸性脂肪酵素缺乏或缺乏引起的。這種酵素的缺乏會導致溶酵素體的結構異常，從而導致體內細胞內各種有毒物質的積累。大約有 50 種溶酵素體貯積病，它們會傷害許多不同的器官，包括心臟、大腦、皮膚、骨骼和中樞神經系統。更多的溶酵素體貯積病不斷被發現。儘管目前正在進行治療幾種溶酵素體貯積病的臨床試驗，但許多溶酵素體貯積病目前還沒有獲得批准的治療方法。

一系列被稱為溶酵素體貯積病的遺傳性代謝疾病是由各種體細胞中的酵素缺乏引起的。溶酵素體貯積病治療市場全球增長的主要驅動力是診斷率的提高，這是由於人們對開發治療溶酵素體貯積病的孤兒藥的認識和經濟激勵不斷提高。溶酵素體貯積病患病率的上升、可負擔的產品成本以及越來越多的製藥公司開發治療溶酵素體貯積病的新藥也促進了市場的增長。溶酵素體貯積病治療缺乏和治療成本上升是製約市場增長的因素。

內容

第一章介紹

第 2 章執行摘要

第 3 章市場概覽

  • 市場定義和範圍
  • 主要發現
    • 主要投資領域
  • 波特五力分析
  • 主要公司的定位
  • 市場動態
    • 驅動程序
    • 約束因素
    • 機會
  • COVID-19 影響分析

第 4 章。溶酵素體貯積病治療市場：按疾病類型分類

  • 概覽
    • 市場規模和預測
  • 戈謝病
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 法布裡病
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 龐貝綜合症
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 粘多醣貯積症
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 5 章溶酵素體貯積病治療市場：按治療類型分類

  • 概覽
    • 市場規模和預測
  • 酵素替代療法
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 幹細胞療法
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 底物還原療法
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 6 章。溶酵素體貯積病治療市場：按最終用戶分類

  • 概覽
    • 市場規模和預測
  • 醫院
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 醫務室
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 7 章。溶酵素體貯積病治療市場：按地區劃分

  • 概覽
    • 市場規模和預測
  • 北美
    • 主要趨勢和機遇
    • 北美市場規模和預測：按疾病類型
    • 北美市場規模和預測：按治療類型
    • 北美市場規模和預測：按最終用戶分類
    • 北美市場規模和預測：按國家/地區分類
      • 美國
      • 加拿大
      • 墨西哥
  • 歐洲
    • 主要趨勢和機遇
    • 歐洲市場規模和預測：按疾病類型
    • 歐洲市場規模和預測：按治療類型
    • 歐洲市場規模和預測：按最終用戶分類
    • 歐洲市場規模和預測：按國家/地區分類
      • 德國
      • 法國
      • 英國
      • 意大利
      • 西班牙
      • 其他歐洲地區
  • 亞太地區
    • 主要趨勢和機遇
    • 亞太地區市場規模和疾病類型預測
    • 按治療類型劃分的亞太市場規模和預測
    • 亞太市場規模和預測：按最終用戶分類
    • 亞太地區的市場規模和預測：按國家/地區分類
      • 日本
      • 中國
      • 澳大利亞
      • 印度
      • 韓國
      • 其他亞太地區
  • LAMEA
    • 主要趨勢和機遇
    • LAMEA 市場規模和預測：按疾病類型
    • LAMEA 市場規模和預測：按治療類型
    • LAMEA 市場規模和預測：按最終用戶分類
    • LAMEA 市場規模和預測：按國家/地區分類
      • 巴西
      • 沙特阿拉伯
      • 南非
      • LAMEA 的其餘部分

第八章企業情況

  • 簡介
  • 關鍵成功策略
  • 10 家主要公司的產品映射
  • 競賽儀表板
  • 比賽熱圖
  • 主要發展

第 9 章公司簡介

  • Amicus Therapeutics, Inc.
  • Alexion Pharmaceuticals, Inc
  • BioMarin
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Sigilon Therapeutics, Inc
Product Code: A05290

The global lysosomal disease treatment market was valued at $7,572.97 million in 2021, and is projected to reach $14,090.39 million by 2031, registering a CAGR of 6.4% from 2022 to 2031.

Lysosomal disease is caused due to deficiency or absence of lysosomal acid lipase enzyme. The deficiency causes structural abnormalities of lysosome, result in storage of several toxic substances in the body cells. There are about 50 different types of these illnesses, which can harm heart, brain, skin, skeleton, and central nervous system among other physical organs. More lysosomal diseases are continuously being identified. Many lysosomal diseases currently lack an approved drug, despite the fact that clinical trials for prospective therapies for some of these disorders are now in progress.

A set of inherited metabolic diseases known as lysosomal storage disorders are brought on by enzyme deficits in different body cells. Key driver for growth of the global lysosomal disease treatment market includes increasing diagnosis rate, owing to increase in awareness and financial incentives for orphan drug development, which treats lysosomal diseases. In addition, rise in prevalence of lysosomal diseases, affordable product cost, increase in pharmaceutical companies for development of novel medications to treat lysosomal diseases are also responsible for growth of the market. Lack of treatment for lysosomal diseases and high cost of treatments are the factors that restrain growth of the market.

The lysosomal disease treatment market is segmented on the basis of disease type, type of therapy, end user, and region. By disease type, the market is divided into Gaucher's diseases, Fabry diseases, Pompe's syndrome, Mucopolysaccharidosis, and others. The others segment is further classified into aspartylglucosaminuria, batten disease, cystinosis, and glycogen storage disease II. By type of therapy, the market is fragmented into Enzyme replacement therapy, Stem cell therapy, Substrate reduction therapy, and others. By end user, it is segmented into Hospitals, Clinics, and others.  Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Major key players that operate in the global lysosomal disease treatment market include Amicus Therapeutics, Inc, Alexion Pharmaceuticals, Inc, BioMari, Chiese Farmaceutici SpA, Eli Lilly Company, Horizon Therapeutics Plc, Johnson & Johnson (Actelion Pharmaceuticals Ltd), Leadient Biosciences, Inc Novartis AG, Orphazyme A/S, Pfizer Inc, Recordati SpA,  Sanofi (Genzyme Corporation), Sigilon Therapeutics, Inc, and Takeda Pharmaceutical Company Limited (Shire Plc) Valerion Therapeutics, Llc, and Viatris Inc (Mylan NV).

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the lysosomal disease treatment market analysis from 2021 to 2031 to identify the prevailing lysosomal disease treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the lysosomal disease treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global lysosomal disease treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Disease Type

  • Gaucher's Diseases
  • Fabry Diseases
  • Pompe's Syndrome
  • Mucopolysaccharidosis
  • Others

By Type of Therapy

  • Enzyme Replacement Therapy
  • Stem Cell Therapy
  • Substrate Reduction Therapy
  • Others

By End User

  • Hospitals
  • Clinics
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Amicus Therapeutics, Inc.
    • Alexion Pharmaceuticals, Inc
    • BioMarin
    • Johnson & Johnson
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • Takeda Pharmaceutical Company Limited
    • Eli Lilly and Company
    • Sigilon Therapeutics, Inc

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Gaucher's Diseases
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Fabry Diseases
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Pompe's Syndrome
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country
  • 4.5 Mucopolysaccharidosis
    • 4.5.1 Key market trends, growth factors and opportunities
    • 4.5.2 Market size and forecast, by region
    • 4.5.3 Market analysis by country
  • 4.6 Others
    • 4.6.1 Key market trends, growth factors and opportunities
    • 4.6.2 Market size and forecast, by region
    • 4.6.3 Market analysis by country

CHAPTER 5: LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Enzyme Replacement Therapy
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Stem Cell Therapy
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 Substrate Reduction Therapy
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country
  • 5.5 Others
    • 5.5.1 Key market trends, growth factors and opportunities
    • 5.5.2 Market size and forecast, by region
    • 5.5.3 Market analysis by country

CHAPTER 6: LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospitals
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Clinics
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Others
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country

CHAPTER 7: LYSOSOMAL DISEASE TREATMENT MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Disease Type
    • 7.2.3 North America Market size and forecast, by Type of Therapy
    • 7.2.4 North America Market size and forecast, by End User
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Disease Type
      • 7.2.5.1.2 Market size and forecast, by Type of Therapy
      • 7.2.5.1.3 Market size and forecast, by End User
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Disease Type
      • 7.2.5.2.2 Market size and forecast, by Type of Therapy
      • 7.2.5.2.3 Market size and forecast, by End User
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Disease Type
      • 7.2.5.3.2 Market size and forecast, by Type of Therapy
      • 7.2.5.3.3 Market size and forecast, by End User
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Disease Type
    • 7.3.3 Europe Market size and forecast, by Type of Therapy
    • 7.3.4 Europe Market size and forecast, by End User
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Disease Type
      • 7.3.5.1.2 Market size and forecast, by Type of Therapy
      • 7.3.5.1.3 Market size and forecast, by End User
      • 7.3.5.2 France
      • 7.3.5.2.1 Market size and forecast, by Disease Type
      • 7.3.5.2.2 Market size and forecast, by Type of Therapy
      • 7.3.5.2.3 Market size and forecast, by End User
      • 7.3.5.3 U.K.
      • 7.3.5.3.1 Market size and forecast, by Disease Type
      • 7.3.5.3.2 Market size and forecast, by Type of Therapy
      • 7.3.5.3.3 Market size and forecast, by End User
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Disease Type
      • 7.3.5.4.2 Market size and forecast, by Type of Therapy
      • 7.3.5.4.3 Market size and forecast, by End User
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Disease Type
      • 7.3.5.5.2 Market size and forecast, by Type of Therapy
      • 7.3.5.5.3 Market size and forecast, by End User
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Disease Type
      • 7.3.5.6.2 Market size and forecast, by Type of Therapy
      • 7.3.5.6.3 Market size and forecast, by End User
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Disease Type
    • 7.4.3 Asia-Pacific Market size and forecast, by Type of Therapy
    • 7.4.4 Asia-Pacific Market size and forecast, by End User
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Market size and forecast, by Disease Type
      • 7.4.5.1.2 Market size and forecast, by Type of Therapy
      • 7.4.5.1.3 Market size and forecast, by End User
      • 7.4.5.2 China
      • 7.4.5.2.1 Market size and forecast, by Disease Type
      • 7.4.5.2.2 Market size and forecast, by Type of Therapy
      • 7.4.5.2.3 Market size and forecast, by End User
      • 7.4.5.3 Australia
      • 7.4.5.3.1 Market size and forecast, by Disease Type
      • 7.4.5.3.2 Market size and forecast, by Type of Therapy
      • 7.4.5.3.3 Market size and forecast, by End User
      • 7.4.5.4 India
      • 7.4.5.4.1 Market size and forecast, by Disease Type
      • 7.4.5.4.2 Market size and forecast, by Type of Therapy
      • 7.4.5.4.3 Market size and forecast, by End User
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Market size and forecast, by Disease Type
      • 7.4.5.5.2 Market size and forecast, by Type of Therapy
      • 7.4.5.5.3 Market size and forecast, by End User
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Market size and forecast, by Disease Type
      • 7.4.5.6.2 Market size and forecast, by Type of Therapy
      • 7.4.5.6.3 Market size and forecast, by End User
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Disease Type
    • 7.5.3 LAMEA Market size and forecast, by Type of Therapy
    • 7.5.4 LAMEA Market size and forecast, by End User
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Disease Type
      • 7.5.5.1.2 Market size and forecast, by Type of Therapy
      • 7.5.5.1.3 Market size and forecast, by End User
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Market size and forecast, by Disease Type
      • 7.5.5.2.2 Market size and forecast, by Type of Therapy
      • 7.5.5.2.3 Market size and forecast, by End User
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Market size and forecast, by Disease Type
      • 7.5.5.3.2 Market size and forecast, by Type of Therapy
      • 7.5.5.3.3 Market size and forecast, by End User
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Disease Type
      • 7.5.5.4.2 Market size and forecast, by Type of Therapy
      • 7.5.5.4.3 Market size and forecast, by End User

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Amicus Therapeutics, Inc.
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Alexion Pharmaceuticals, Inc
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 BioMarin
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Johnson & Johnson
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Novartis AG
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Pfizer Inc.
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Sanofi
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Takeda Pharmaceutical Company Limited
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Eli Lilly and Company
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Sigilon Therapeutics, Inc
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 2. LYSOSOMAL DISEASE TREATMENT MARKET SIZE, FOR GAUCHER'S DISEASES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. LYSOSOMAL DISEASE TREATMENT MARKET FOR GAUCHER'S DISEASES BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. LYSOSOMAL DISEASE TREATMENT MARKET SIZE, FOR FABRY DISEASES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 5. LYSOSOMAL DISEASE TREATMENT MARKET FOR FABRY DISEASES BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 6. LYSOSOMAL DISEASE TREATMENT MARKET SIZE, FOR POMPE'S SYNDROME, BY REGION, 2021-2031 ($MILLION)
  • TABLE 7. LYSOSOMAL DISEASE TREATMENT MARKET FOR POMPE'S SYNDROME BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 8. LYSOSOMAL DISEASE TREATMENT MARKET SIZE, FOR MUCOPOLYSACCHARIDOSIS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 9. LYSOSOMAL DISEASE TREATMENT MARKET FOR MUCOPOLYSACCHARIDOSIS BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 10. LYSOSOMAL DISEASE TREATMENT MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 11. LYSOSOMAL DISEASE TREATMENT MARKET FOR OTHERS BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 12. GLOBAL LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
  • TABLE 13. LYSOSOMAL DISEASE TREATMENT MARKET SIZE, FOR ENZYME REPLACEMENT THERAPY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. LYSOSOMAL DISEASE TREATMENT MARKET FOR ENZYME REPLACEMENT THERAPY BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 15. LYSOSOMAL DISEASE TREATMENT MARKET SIZE, FOR STEM CELL THERAPY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 16. LYSOSOMAL DISEASE TREATMENT MARKET FOR STEM CELL THERAPY BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 17. LYSOSOMAL DISEASE TREATMENT MARKET SIZE, FOR SUBSTRATE REDUCTION THERAPY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 18. LYSOSOMAL DISEASE TREATMENT MARKET FOR SUBSTRATE REDUCTION THERAPY BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 19. LYSOSOMAL DISEASE TREATMENT MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 20. LYSOSOMAL DISEASE TREATMENT MARKET FOR OTHERS BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 21. GLOBAL LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 22. LYSOSOMAL DISEASE TREATMENT MARKET SIZE, FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 23. LYSOSOMAL DISEASE TREATMENT MARKET FOR HOSPITALS BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 24. LYSOSOMAL DISEASE TREATMENT MARKET SIZE, FOR CLINICS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 25. LYSOSOMAL DISEASE TREATMENT MARKET FOR CLINICS BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 26. LYSOSOMAL DISEASE TREATMENT MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 27. LYSOSOMAL DISEASE TREATMENT MARKET FOR OTHERS BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 28. LYSOSOMAL DISEASE TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 29. NORTH AMERICA LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 30. NORTH AMERICA LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
  • TABLE 31. NORTH AMERICA LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 32. NORTH AMERICA LYSOSOMAL DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 33. U.S. LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 34. U.S. LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
  • TABLE 35. U.S. LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 36. CANADA LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 37. CANADA LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
  • TABLE 38. CANADA LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 39. MEXICO LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 40. MEXICO LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
  • TABLE 41. MEXICO LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 42. EUROPE LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 43. EUROPE LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
  • TABLE 44. EUROPE LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 45. EUROPE LYSOSOMAL DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 46. GERMANY LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 47. GERMANY LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
  • TABLE 48. GERMANY LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 49. FRANCE LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 50. FRANCE LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
  • TABLE 51. FRANCE LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 52. U.K. LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 53. U.K. LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
  • TABLE 54. U.K. LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 55. ITALY LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 56. ITALY LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
  • TABLE 57. ITALY LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 58. SPAIN LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 59. SPAIN LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
  • TABLE 60. SPAIN LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 61. REST OF EUROPE LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 62. REST OF EUROPE LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
  • TABLE 63. REST OF EUROPE LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 64. ASIA-PACIFIC LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 65. ASIA-PACIFIC LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
  • TABLE 66. ASIA-PACIFIC LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 67. ASIA-PACIFIC LYSOSOMAL DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 68. JAPAN LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 69. JAPAN LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
  • TABLE 70. JAPAN LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 71. CHINA LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 72. CHINA LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
  • TABLE 73. CHINA LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 74. AUSTRALIA LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 75. AUSTRALIA LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
  • TABLE 76. AUSTRALIA LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 77. INDIA LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 78. INDIA LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
  • TABLE 79. INDIA LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 80. SOUTH KOREA LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 81. SOUTH KOREA LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
  • TABLE 82. SOUTH KOREA LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 83. REST OF ASIA-PACIFIC LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 84. REST OF ASIA-PACIFIC LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
  • TABLE 85. REST OF ASIA-PACIFIC LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 86. LAMEA LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 87. LAMEA LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
  • TABLE 88. LAMEA LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 89. LAMEA LYSOSOMAL DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 90. BRAZIL LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 91. BRAZIL LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
  • TABLE 92. BRAZIL LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 93. SAUDI ARABIA LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 94. SAUDI ARABIA LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
  • TABLE 95. SAUDI ARABIA LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 96. SOUTH AFRICA LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 97. SOUTH AFRICA LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
  • TABLE 98. SOUTH AFRICA LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 99. REST OF LAMEA LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 100. REST OF LAMEA LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY, 2021-2031 ($MILLION)
  • TABLE 101. REST OF LAMEA LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 102.AMICUS THERAPEUTICS, INC.: COMPANY SNAPSHOT
  • TABLE 103.AMICUS THERAPEUTICS, INC.: OPERATING SEGMENTS
  • TABLE 104.AMICUS THERAPEUTICS, INC.: PRODUCT PORTFOLIO
  • TABLE 105.AMICUS THERAPEUTICS, INC.: NET SALES,
  • TABLE 106.AMICUS THERAPEUTICS, INC.: KEY STRATERGIES
  • TABLE 107.ALEXION PHARMACEUTICALS, INC: COMPANY SNAPSHOT
  • TABLE 108.ALEXION PHARMACEUTICALS, INC: OPERATING SEGMENTS
  • TABLE 109.ALEXION PHARMACEUTICALS, INC: PRODUCT PORTFOLIO
  • TABLE 110.ALEXION PHARMACEUTICALS, INC: NET SALES,
  • TABLE 111.ALEXION PHARMACEUTICALS, INC: KEY STRATERGIES
  • TABLE 112.BIOMARIN: COMPANY SNAPSHOT
  • TABLE 113.BIOMARIN: OPERATING SEGMENTS
  • TABLE 114.BIOMARIN: PRODUCT PORTFOLIO
  • TABLE 115.BIOMARIN: NET SALES,
  • TABLE 116.BIOMARIN: KEY STRATERGIES
  • TABLE 117.JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 118.JOHNSON & JOHNSON: OPERATING SEGMENTS
  • TABLE 119.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 120.JOHNSON & JOHNSON: NET SALES,
  • TABLE 121.JOHNSON & JOHNSON: KEY STRATERGIES
  • TABLE 122.NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 123.NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 124.NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 125.NOVARTIS AG: NET SALES,
  • TABLE 126.NOVARTIS AG: KEY STRATERGIES
  • TABLE 127.PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 128.PFIZER INC.: OPERATING SEGMENTS
  • TABLE 129.PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 130.PFIZER INC.: NET SALES,
  • TABLE 131.PFIZER INC.: KEY STRATERGIES
  • TABLE 132.SANOFI: COMPANY SNAPSHOT
  • TABLE 133.SANOFI: OPERATING SEGMENTS
  • TABLE 134.SANOFI: PRODUCT PORTFOLIO
  • TABLE 135.SANOFI: NET SALES,
  • TABLE 136.SANOFI: KEY STRATERGIES
  • TABLE 137.TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT
  • TABLE 138.TAKEDA PHARMACEUTICAL COMPANY LIMITED: OPERATING SEGMENTS
  • TABLE 139.TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT PORTFOLIO
  • TABLE 140.TAKEDA PHARMACEUTICAL COMPANY LIMITED: NET SALES,
  • TABLE 141.TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY STRATERGIES
  • TABLE 142.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 143.ELI LILLY AND COMPANY: OPERATING SEGMENTS
  • TABLE 144.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 145.ELI LILLY AND COMPANY: NET SALES,
  • TABLE 146.ELI LILLY AND COMPANY: KEY STRATERGIES
  • TABLE 147.SIGILON THERAPEUTICS, INC: COMPANY SNAPSHOT
  • TABLE 148.SIGILON THERAPEUTICS, INC: OPERATING SEGMENTS
  • TABLE 149.SIGILON THERAPEUTICS, INC: PRODUCT PORTFOLIO
  • TABLE 150.SIGILON THERAPEUTICS, INC: NET SALES,
  • TABLE 151.SIGILON THERAPEUTICS, INC: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.LYSOSOMAL DISEASE TREATMENT MARKET SEGMENTATION
  • FIGURE 2.LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031
  • FIGURE 3.LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.LYSOSOMAL DISEASE TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.LYSOSOMAL DISEASE TREATMENT MARKET,BY DISEASE TYPE,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF GAUCHER'S DISEASES LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF FABRY DISEASES LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF POMPE'S SYNDROME LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF MUCOPOLYSACCHARIDOSIS LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF OTHERS LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031(%)
  • FIGURE 18.LYSOSOMAL DISEASE TREATMENT MARKET,BY TYPE OF THERAPY,2021(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF ENZYME REPLACEMENT THERAPY LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF STEM CELL THERAPY LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF SUBSTRATE REDUCTION THERAPY LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF OTHERS LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031(%)
  • FIGURE 23.LYSOSOMAL DISEASE TREATMENT MARKET,BY END USER,2021(%)
  • FIGURE 24.COMPARATIVE SHARE ANALYSIS OF HOSPITALS LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031(%)
  • FIGURE 25.COMPARATIVE SHARE ANALYSIS OF CLINICS LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031(%)
  • FIGURE 26.COMPARATIVE SHARE ANALYSIS OF OTHERS LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031(%)
  • FIGURE 27.LYSOSOMAL DISEASE TREATMENT MARKET BY REGION,2021
  • FIGURE 28.U.S. LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 29.CANADA LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 30.MEXICO LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 31.GERMANY LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 32.FRANCE LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 33.U.K. LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 34.ITALY LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 35.SPAIN LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 36.REST OF EUROPE LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 37.JAPAN LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 38.CHINA LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 39.AUSTRALIA LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 40.INDIA LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 41.SOUTH KOREA LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 42.REST OF ASIA-PACIFIC LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 43.BRAZIL LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 44.SAUDI ARABIA LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 45.SOUTH AFRICA LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 46.REST OF LAMEA LYSOSOMAL DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 47. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 48. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 49. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 50.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 51.COMPETITIVE DASHBOARD
  • FIGURE 52.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 53.AMICUS THERAPEUTICS, INC..: NET SALES ,($MILLION)
  • FIGURE 54.ALEXION PHARMACEUTICALS, INC.: NET SALES ,($MILLION)
  • FIGURE 55.BIOMARIN.: NET SALES ,($MILLION)
  • FIGURE 56.JOHNSON & JOHNSON.: NET SALES ,($MILLION)
  • FIGURE 57.NOVARTIS AG.: NET SALES ,($MILLION)
  • FIGURE 58.PFIZER INC..: NET SALES ,($MILLION)
  • FIGURE 59.SANOFI.: NET SALES ,($MILLION)
  • FIGURE 60.TAKEDA PHARMACEUTICAL COMPANY LIMITED.: NET SALES ,($MILLION)
  • FIGURE 61.ELI LILLY AND COMPANY.: NET SALES ,($MILLION)
  • FIGURE 62.SIGILON THERAPEUTICS, INC.: NET SALES ,($MILLION)